Krystexxa® (Pegloticase)
Krystexxa® (pegloticase) (Intravenous) Document Number: IC-0158 Last Review Date: 10/01/2020 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 10/2019, 10/2020 I. Length of Authorization Coverage is provided for six months and will be eligible for renewal. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Krystexxa 8 mg/mL single-use vial: 2 vials every 28 days B. Max Units (per dose and over time) [HCPCS Unit]: • 16 billable units every 28 days 1 III. Initial Approval Criteria Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND • Patients at higher risk for glucose-6-phosphate dehydrogenase (G6PD) deficiency should be screened and found negative for G6PD before starting Krystexxa; AND • Documentation of baseline serum uric acid level > 8 mg/dL (current lab reports are required for renewal); AND Universal Criteria 1,2 • Therapy will not be given in combination with other urate lowering therapies such as allopurinol, febuxostat, probenecid, lesinurad, etc.; AND Chronic Gout † Ф 1 • Documented contraindication, intolerance, or clinical failure (i.e., inability to reduce serum uric acid to < 6 mg/dL) during a minimum (3) month trial on previous therapy with maximum tolerated dose of xanthine oxidase inhibitors (e.g., allopurinol or febuxostat) or uricosuric agents (e.g., probenecid, lenisurad, etc.); AND • Patient has one of the following: Proprietary & Confidential © 2020 Magellan Health, Inc. o 2 or more gout flares per year that were inadequately controlled by colchicine, nonsteroidal anti-inflammatory drugs (NSAIDS), or oral or injectable corticosteroids; OR o Nonresolving subcutaneous tophi † FDA-labeled indication(s); Ф Orphan Drug 1 IV.
[Show full text]